Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184858 | 1.00 | TSHR (0.37) | TSHRCYP11B2CYP11B1ABL1KDR | |
| SCHEMBL15334774 | 0.84 | TSHR (0.44) | TSHRCYP11B2CYP11B1HTTRAF1 | |
| SCHEMBL3559922 | 0.79 | TSHR (0.41) | TSHRCYP11B2CYP11B1HTTRAF1 | |
| SCHEMBL9948298 | 0.77 | — | — | |
| SCHEMBL152386 | 0.75 | — | — | |
| SCHEMBL30551593 | 0.74 | TSHR (0.37) | TSHRCYP11B2CYP11B1RAF1ALDH1A1 | |
| SCHEMBL14809369 | 0.74 | CYP11B2 (0.45) | TSHRCYP11B2CYP11B1 | |
| SCHEMBL3825639 | 0.74 | CYP11B2 (0.39) | TSHRCYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL2931936 | 0.74 | CSNK1A1 (0.34) | CYP11B2CYP11B1ABL1KDRHTT | |
| SCHEMBL13755084 | 0.74 | KDM1A (0.41) | TSHRCYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709722-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024233547-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| EP-1999110-B1 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | UCB PHARMA, S.A. (BE) | 2009-09-03 | — | — | US | disclosed |
| EP-2004188-A4 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2004188-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TSHR 4658/4885CYP11B2 1461/4885CYP11B1 3367/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | TSHR 4658/4885CYP11B2 1461/4885CYP11B1 3367/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | TSHR 4658/4885CYP11B2 1461/4885CYP11B1 3367/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | TSHR 1753/4885CYP11B2 11/4885CYP11B1 9/4885 |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | NPM1, XPO4, BRD7 | TSHR 2348/4885CYP11B2 1525/4885CYP11B1 2018/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | TSHR 1917/4885CYP11B2 8/4885CYP11B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.